How much profit has MEI Pharma made this year?
MEI Pharma has made 24.59 M USD this year.
MEI Pharma Net Income 2024
MEI Pharma Net Income
24.59 M USD
Ticker
MEIP
ISIN
US55279B2025
WKN
A1KATX
In 2024, MEI Pharma's profit amounted to 24.59 M USD, a -177.23% increase from the -31.84 M USD profit recorded in the previous year.
The MEI Pharma Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | -7.61 |
| 2027e | -8.08 |
| 2026e | -25.2 |
| 2025e | -38.65 |
| 2024e | 24.59 |
| 2023 | -31.84 |
| 2022 | -54.45 |
| 2021 | -41.31 |
| 2020 | -47.17 |
| 2019 | -16.82 |
| 2018 | -40.07 |
| 2017 | 2.67 |
| 2016 | -20.86 |
| 2015 | -32.69 |
| 2014 | -27.15 |
| 2013 | -11.19 |
| 2012 | -7.52 |
| 2011 | -6.78 |
| 2010 | -7.9 |
| 2009 | -11.18 |
| 2008 | -12.41 |
| 2007 | -13.82 |
| 2006 | -7.39 |
| 2005 | -6.42 |
| 2004 | -8.54 |
MEI Pharma Revenue, EBIT, Net Income US55279B2025 · A1KATX
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into MEI Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MEI Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MEI Pharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of MEI Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into MEI Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing MEI Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MEI Pharma’s growth potential.
MEI Pharma Revenue, Profit, and EBIT History
| Date | MEI Pharma Revenue | MEI Pharma EBIT | MEI Pharma Net Income |
|---|---|---|---|
| 2029e | 1.44 B undefined | 0 undefined | 0 undefined |
| 2028e | 25.5 M undefined | -36 M undefined | -7.61 M undefined |
| 2027e | 25.5 M undefined | -33.29 M undefined | -8.08 M undefined |
| 2026e | 25.5 M undefined | -29.94 M undefined | -25.2 M undefined |
| 2025e | 6.38 M undefined | -41.96 M undefined | -38.65 M undefined |
| 2024e | 66.6 M undefined | 23.63 M undefined | 24.59 M undefined |
| 2023 | 48.82 M undefined | -36.76 M undefined | -31.84 M undefined |
| 2022 | 40.7 M undefined | -75.48 M undefined | -54.45 M undefined |
| 2021 | 34.8 M undefined | -60.42 M undefined | -41.31 M undefined |
| 2020 | 27.76 M undefined | -25.7 M undefined | -47.17 M undefined |
| 2019 | 4.92 M undefined | -46.25 M undefined | -16.82 M undefined |
| 2018 | 1.62 M undefined | -28.59 M undefined | -40.07 M undefined |
| 2017 | 23.25 M undefined | 2.38 M undefined | 2.67 M undefined |
| 2016 | 0 undefined | -21 M undefined | -20.86 M undefined |
| 2015 | 0 undefined | -32.77 M undefined | -32.69 M undefined |
| 2014 | 0 undefined | -27.23 M undefined | -27.15 M undefined |
| 2013 | 0 undefined | -11.22 M undefined | -11.19 M undefined |
| 2012 | 0 undefined | -8.39 M undefined | -7.52 M undefined |
| 2011 | 0 undefined | -6.45 M undefined | -6.78 M undefined |
| 2010 | 0 undefined | -7.98 M undefined | -7.9 M undefined |
| 2009 | 0 undefined | -11.41 M undefined | -11.18 M undefined |
| 2008 | 670,000 undefined | -12.41 M undefined | -12.41 M undefined |
| 2007 | 650,000 undefined | -13.82 M undefined | -13.82 M undefined |
| 2006 | 450,000 undefined | -7.39 M undefined | -7.39 M undefined |
| 2005 | 310,000 undefined | -6.42 M undefined | -6.42 M undefined |
| 2004 | 190,000 undefined | -8.54 M undefined | -8.54 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 190,000 USD | -8.54 M USD | -8.54 M USD |
| 2005 | 310,000 USD | -6.42 M USD | -6.42 M USD |
| 2006 | 450,000 USD | -7.39 M USD | -7.39 M USD |
| 2007 | 650,000 USD | -13.82 M USD | -13.82 M USD |
| 2008 | 670,000 USD | -12.41 M USD | -12.41 M USD |
| 2009 | 0 USD | -11.41 M USD | -11.18 M USD |
| 2010 | 0 USD | -7.98 M USD | -7.9 M USD |
| 2011 | 0 USD | -6.45 M USD | -6.78 M USD |
| 2012 | 0 USD | -8.39 M USD | -7.52 M USD |
| 2013 | 0 USD | -11.22 M USD | -11.19 M USD |
| 2014 | 0 USD | -27.23 M USD | -27.15 M USD |
| 2015 | 0 USD | -32.77 M USD | -32.69 M USD |
| 2016 | 0 USD | -21 M USD | -20.86 M USD |
| 2017 | 23.25 M USD | 2.38 M USD | 2.67 M USD |
| 2018 | 1.62 M USD | -28.59 M USD | -40.07 M USD |
| 2019 | 4.92 M USD | -46.25 M USD | -16.82 M USD |
| 2020 | 27.76 M USD | -25.7 M USD | -47.17 M USD |
| 2021 | 34.8 M USD | -60.42 M USD | -41.31 M USD |
| 2022 | 40.7 M USD | -75.48 M USD | -54.45 M USD |
| 2023 | 48.82 M USD | -36.76 M USD | -31.84 M USD |
| 2024e | 66.6 M USD | 23.63 M USD | 24.59 M USD |
| 2025e | 6.38 M USD | -41.96 M USD | -38.65 M USD |
| 2026e | 25.5 M USD | -29.94 M USD | -25.2 M USD |
| 2027e | 25.5 M USD | -33.29 M USD | -8.08 M USD |
| 2028e | 25.5 M USD | -36 M USD | -7.61 M USD |
| 2029e | 1.44 B USD | 0 USD | 0 USD |
MEI Pharma stock margins US55279B2025 · A1KATX
The MEI Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MEI Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MEI Pharma.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the MEI Pharma's sales revenue. A higher gross margin percentage indicates that the MEI Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the MEI Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the MEI Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MEI Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MEI Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MEI Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
MEI Pharma Margin History
| MEI Pharma Gross margin | MEI Pharma Profit margin | MEI Pharma EBIT margin | MEI Pharma Profit margin |
|---|---|---|---|
| 2029e | 100 % | 0 % | 0 % |
| 2028e | 100 % | -141.19 % | -29.84 % |
| 2027e | 100 % | -130.54 % | -31.7 % |
| 2026e | 100 % | -117.41 % | -98.83 % |
| 2025e | 100 % | -658.13 % | -606.33 % |
| 2024e | 100 % | 35.48 % | 36.92 % |
| 2023 | 100 % | -75.3 % | -65.22 % |
| 2022 | 100 % | -185.45 % | -133.78 % |
| 2021 | 95.95 % | -173.62 % | -118.71 % |
| 2020 | 90.38 % | -92.58 % | -169.92 % |
| 2019 | 13.21 % | -940.04 % | -341.87 % |
| 2018 | -108.64 % | -1,764.81 % | -2,473.46 % |
| 2017 | 78.49 % | 10.24 % | 11.48 % |
| 2016 | 100 % | 0 % | 0 % |
| 2015 | 100 % | 0 % | 0 % |
| 2014 | 100 % | 0 % | 0 % |
| 2013 | 100 % | 0 % | 0 % |
| 2012 | 100 % | 0 % | 0 % |
| 2011 | 100 % | 0 % | 0 % |
| 2010 | 100 % | 0 % | 0 % |
| 2009 | 100 % | 0 % | 0 % |
| 2008 | 100 % | -1,852.24 % | -1,852.24 % |
| 2007 | 100 % | -2,126.15 % | -2,126.15 % |
| 2006 | 100 % | -1,642.22 % | -1,642.22 % |
| 2005 | 100 % | -2,070.97 % | -2,070.97 % |
| 2004 | 100 % | -4,494.74 % | -4,494.74 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 100 % | -4,494.74 % | -4,494.74 % |
| 2005 | 100 % | -2,070.97 % | -2,070.97 % |
| 2006 | 100 % | -1,642.22 % | -1,642.22 % |
| 2007 | 100 % | -2,126.15 % | -2,126.15 % |
| 2008 | 100 % | -1,852.24 % | -1,852.24 % |
| 2009 | 100 % | 0 % | 0 % |
| 2010 | 100 % | 0 % | 0 % |
| 2011 | 100 % | 0 % | 0 % |
| 2012 | 100 % | 0 % | 0 % |
| 2013 | 100 % | 0 % | 0 % |
| 2014 | 100 % | 0 % | 0 % |
| 2015 | 100 % | 0 % | 0 % |
| 2016 | 100 % | 0 % | 0 % |
| 2017 | 78.49 % | 10.24 % | 11.48 % |
| 2018 | -108.64 % | -1,764.81 % | -2,473.46 % |
| 2019 | 13.21 % | -940.04 % | -341.87 % |
| 2020 | 90.38 % | -92.58 % | -169.92 % |
| 2021 | 95.95 % | -173.62 % | -118.71 % |
| 2022 | 100 % | -185.45 % | -133.78 % |
| 2023 | 100 % | -75.3 % | -65.22 % |
| 2024e | 100 % | 35.48 % | 36.92 % |
| 2025e | 100 % | -658.13 % | -606.33 % |
| 2026e | 100 % | -117.41 % | -98.83 % |
| 2027e | 100 % | -130.54 % | -31.7 % |
| 2028e | 100 % | -141.19 % | -29.84 % |
| 2029e | 100 % | 0 % | 0 % |
MEI Pharma Aktienanalyse
What does MEI Pharma do?
MEI Pharma Inc. is a pharmaceutical company focused on the development and commercialization of cancer-related therapeutics. It was founded in 2000 and is headquartered in San Diego, California. MEI Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding MEI Pharma's Profit Margins
The profit margins of MEI Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of MEI Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating MEI Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
MEI Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When MEI Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about MEI Pharma Stock
How has the profit developed compared to last year?
The profit has increased by -177.23% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does MEI Pharma publish its earnings?
MEI Pharma publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of MEI Pharma?
The profits of MEI Pharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of MEI Pharma?
You can learn more about the earnings of MEI Pharma by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does MEI Pharma pay?
Over the past 12 months, MEI Pharma paid a dividend of 1.75 USD . This corresponds to a dividend yield of about 61.62 %. For the coming 12 months, MEI Pharma is expected to pay a dividend of 1.75 USD.
What is the dividend yield of MEI Pharma?
The current dividend yield of MEI Pharma is 61.62 %.
When does MEI Pharma pay dividends?
MEI Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MEI Pharma?
MEI Pharma paid dividends every year for the past 0 years.
What is the dividend of MEI Pharma?
For the upcoming 12 months, dividends amounting to 1.75 USD are expected. This corresponds to a dividend yield of 61.62 %.
In which sector is MEI Pharma located?
MEI Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von MEI Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MEI Pharma from 12/6/2023 amounting to 1.75 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2023.
When did MEI Pharma pay the last dividend?
The last dividend was paid out on 12/6/2023.
What was the dividend of MEI Pharma in the year 2023?
In the year 2023, MEI Pharma distributed 0 USD as dividends.
In which currency does MEI Pharma pay out the dividend?
The dividends of MEI Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MEI Pharma stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MEI Pharma
Our stock analysis for MEI Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MEI Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
